Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
== Health effects == Exposure to PFAS typically comes from consumption of PFAS contaminated food or water and inhalation of airborne PFAS. Once in the body, some PFAS have half-lives of over eight years. PFAS are not broken down in the body, but instead cleared from the body in urine. This lengthy residence time and widespread environmental contamination lead to accumulation of PFAS that may cause adverse health outcomes. Given the large diversity of PFAS compounds, there is a lack of high-quality epidemiological data on the associations between most specific PFAS chemicals and toxicological impacts.
=== 14 April === One person was killed in a Russian airstrike in Donetsk Oblast. Another person was killed by Russian shelling in Sumy Oblast. Russia claimed that it had shot down all ten drones launched by Ukraine at Krasnodar Krai.
== Mechanism of action == After the venom has entered the body via the wasp sting, it enters the bloodstream, where it will be diluted in the blood and distributed through the organism. Pompilidotoxins target the sodium channels, so the toxin reaches its target sites via the distribution by the bloodstream. Research by Sahara et.al. (2000) has suggested that α-PMTX might slow or block the conformational changes that are necessary for the fast inactivation of voltage gated sodium channels. This causes the intracellular sodium concentration to increase. They hypothesise that this effect could be caused by the α-PMTX binding to similar elements of the neurotoxin receptor site 3 on the extracellular surface of the sodium channel. α-PMTX also enhances both the inhibitory postsynaptic potentials (IPSPs) and the excitatory postsynaptic potentials (EPSPs). The eventual paralysis of the spider is caused by the prolonged membrane depolarization, which is induced by the EPSPs. However, when the fast inactivation is slowed or blocked by channel blocker like PMTX, the membrane will not repolarize properly, but stay in a depolarized state instead. The long-lasting depolarisation leads to paralysis. A study by Konno et.al. (2001) has found that the positively charged amino acids in β-PMTX likely bind to the Glu-1616 site on the D4S3-S4 loop of the sodium channel. This indicates that the positive charges of PMTXs are a crucial part of the toxins, as they are likely involved in the electrostatic bonding between the toxin and the sodium channel.
=== Liver === The liver parenchyma is the functional tissue of the organ made up of around 80% of the liver volume as hepatocytes. The other main type of liver cells are non-parenchymal. Non-parenchymal cells constitute 40% of the total number of liver cells but only 6.5% of its volume.
Sources: en.wikipedia.org
== January 8, 1982 (Friday) == To end a federal antitrust suit that had been brought in 1974 by the U.S. Department of Justice, the telephone monopoly American Telephone & Telegraph (AT&T) agreed to sell its 22 individual Bell System companies that had controlled most U.S. telephone lines. On the same day, the Department of Justice dropped its 12-year-old antitrust suit against International Business Machines (IBM), ending a trial that had started on May 19, 1975. The Umkhonto we Sizwe paramilitary force of South Africa's anti-apartheid African National Congress, carried out an attack on the construction site of the Koeberg Nuclear Power Station, planned to be the white South African government's first nuclear power plant, causing 500 million rands worth of damage and setting back the completion date by 18 months. The first White House meeting concerning Project Excalibur, the proposed Strategic Defense Initiative (nicknamed the "Star Wars defense") for the United States against an enemy missile attack, took place as Edward Teller, Karl Bendetsen, William Wilson and Joseph Coors made a one-hour presentation to U.S. President Ronald Reagan for a satellite with lasers that could destroy nuclear missiles after their launch.
Often described as a de facto one-party state because of its uncommon longevity for a nominal liberal democracy, some activists and opposition politicians view the PAP government's tight regulation of political and media activities, along with its stringent laws, as an infringement on political rights. In response, the PAP introduced several significant political changes, including the creation of the Non-constituency Members of Parliament (NCMPs) scheme from the 1984 election, which allowed a limited number of the best performing losing opposition candidates to be appointed as MPs. Group representation constituencies (GRCs) were subsequently introduced in the 1988 election as multi-member electoral divisions intended to guarantee minority representation in parliament, although the opposition has accused the scheme of enabling gerrymandering. In addition, Nominated Members of Parliament (NMPs) were introduced in 1990 to allow non-elected and non-partisan representatives from diverse professional fields to serve in parliament. The constitution was amended in 1991 to provide for an elected president with veto powers over the use of past reserves and key public service appointments. The first such election was held in 1993. In 1990, Goh Chok Tong succeeded Lee and became Singapore's second prime minister, leading the PAP into the 1991 election. During Goh's tenure, the country went through the 1997 Asian financial crisis and the 2002–2004 SARS outbreak. In 2004, Lee Hsien Loong, the eldest son of Lee Kuan Yew, became the country's third prime minister.
== Humans == In contrast to chimpanzees, a common morphological variant found in humans called hirsuties coronae glandis, or pearly penile papules, are substantially larger, appear to be an outpocketing of both surface and underlying connective tissue layers, and lack the rich innervation seen in other animals. These are sometimes described as vestigial remnants of penile spines. However, the relationship between the structures is still uncertain. When the hominin lineage split into the genera Homo and Pan, a regulatory DNA sequence associated with the formation of small keratinized penile spines was lost in the Homo lineage. This simplification of penis anatomy may be associated with the sexual habits of humans. In some species which retain full expression, penile spines contribute to increased sexual sensation and quicker orgasms. An hCONDEL (highly conserved region of DNA that contains deletions in humans) located near the locus of the androgen receptor gene may be responsible for the loss of penile spines in humans.
=== True cobras === The cobras (Naja spp.) are a medically important group of snakes due to the number of bites and fatalities they cause across their geographical range. The genus Naja consists of 20 to 22 species, but has undergone several taxonomic revisions in recent years, so sources vary greatly. They range throughout Africa (including some parts of the Sahara where Naja haje can be found), Southwest Asia, Central Asia, South Asia, East Asia, and Southeast Asia. The most recent revision, listed 28 species after the synonymisation of Boulengerina and Paranaja with Naja. But unlike some other members of the family Elapidae (the species of the genus Bungarus, genus Oxyuranus, genus Pseudohaje, and especially genus Dendroaspis), half of the bites by many species of both African and Asian origin of the genus Naja are "dry bites" (a dry bite is a bite by a venomous snake in which no venom is released). Roughly 45–50% of bites by most cobra species are dry bites and thus don't cause envenomation. Some of the species that are known and documented to deliver dry bites in a majority of cases include Naja naja, Naja kaouthia, Naja sputatrix, Naja siamensis, Naja haje, Naja annulifera, Naja anchietae, and Naja nigricollis. Some species will inject venom in the majority of their bites, but still deliver high number of dry bites (40–45%) include: Naja sumatrana, Naja melanoleuca, Naja atra, Naja mossambica and Naja katiensis. Within this genus, there are a few species in which dry bites are very rare. Envenoming occurs in at least 75–80% of bite cases involving these species.
The report of the Royal Commission, published in 1937, recommended the establishment of a Regional Council for Northumberland and Tyneside (to be called the "Northumberland Regional Council") to administer services that needed to be exercised over a wide area, with a second tier of smaller units for other local-government purposes. The second-tier units would form by amalgamating the various existing boroughs and districts. The county boroughs in the area would lose their status. Within this area, a single municipality would be formed covering the four county boroughs of Newcastle, Gateshead, Tynemouth, South Shields and other urban districts and boroughs. A minority report proposed amalgamation of Newcastle, Gateshead, Wallsend, Jarrow, Felling, Gosforth, Hebburn and Newburn into a single "county borough of Newcastle-on-Tyneside". The 1937 proposals never came into operation: local authorities could not agree on a scheme and the legislation of the time did not allow central government to compel one. Tyneside (excluding Sunderland) was a special review area under the Local Government Act 1958. The Local Government Commission for England came back with a recommendation to create a new county of Tyneside based on the review area, divided into four separate boroughs. This was not implemented. The Redcliffe-Maud Report proposed a Tyneside unitary authority, again excluding Sunderland, which would have set up a separate East Durham unitary authority.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.